GABAmimetic drugs are effective in the treatment of hyperkinetic involuntary motor disorders like tardive dyskinesia. Several therapeutic pharmacologic strategies have been identified, including direct‐acting agonists, reuptake blockers, and degradation inhibitors. This pharmacologic response, in addition to providing clinical efficacy data, has led to the speculation that GABA is pathophysiologically involved in tardive dyskinesia. The most potent GABAmimetic compounds have psychotomimetic effects, but some of the weaker GABA agonists are clinically effective for dyskinesias without severe cognitive side effects. Thus, GABA agonists are likely to be available soon as practical treatments for tardive dyskinesia.
|Original language||English (US)|
|Number of pages||7|
|Journal||Drug Development Research|
|State||Published - 1990|
- tardive dyskinesia
ASJC Scopus subject areas
- Drug Discovery